ArticleBiology2025
Hepatocyte-Specific Transcriptional Responses to Liver-Targeted Delivery of a Soluble Epoxide Hydrolase Inhibitor in a Mouse Model of Alcohol-Associated Liver Disease.
Dennis R Warner, Jeffrey B Warner, Josiah E Hardesty, Yasmeen Abdelfadil, Chirag Soni, Philip Bauer, Claudio Maldonado, Craig J McClain, Irina A Kirpich
Abstract read
In one paragraphArticle in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Dennis R WarnerDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Jeffrey B WarnerDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0003-2022-7854 Josiah E HardestyDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0003-1955-3046 Yasmeen AbdelfadilDepartment of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, USA.
Chirag SoniEndo ProTech, Louisville, KY 40202, USA.
Philip BauerEndo ProTech, Louisville, KY 40202, USA.
Claudio MaldonadoEndo ProTech, Louisville, KY 40202, USA.
Craig J McClainDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0002-7219-8939 Irina A KirpichDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, USA.
Funding
Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI BARVE, SHIRISH S · 2016 to 2025
$24.1MThe Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN · 2016 to 2026
$17.9MUOFL ENVIRONMENTAL HEALTH SCIENCES TRAINING PROGRAMT32ES011564 · NIEHS · UNIVERSITY OF LOUISVILLE · PI David W Hein, John Pierce Wise · 2004 to 2026
$7.1MIntegrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9MRole of Soluble Epoxide Hydrolase in Alcohol-Associated Liver DiseaseR01AA028905 · NIAAA · UNIVERSITY OF LOUISVILLE · PI Irina A. Kirpich · 2022 to 2026
$2.1MPilot Trial UO1 DUR-928U01AA026934 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2018 to 2022
$356kRestoration and preservation of hepatic cardiolipin levels promotes liver regeneration in AHK99AA030627 · NIAAA · UNIVERSITY OF LOUISVILLE · PI HARDESTY, JOSIAH E · 2022 to 2023
$269kRvD1-FPR2 signaling ameliorates alcoholic liver diseaseF32AA027950 · NIAAA · UNIVERSITY OF LOUISVILLE · PI HARDESTY, JOSIAH E · 2020 to 2022
$164ksEH Inhibition in Alcoholic Liver Disease: A Novel Therapeutic StrategyF31AA028423 · NIAAA · UNIVERSITY OF LOUISVILLE · PI WARNER, JEFFREY B · 2020 to 2022
$92kInstitutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under P20GM113226National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health P50AA024337NIAAA NIH HHS F31 AA028423NIAAA NIH HHS F32 AA027950NIAAA NIH HHS K99 AA030627NIAAA NIH HHS P50 AA024337NIAAA NIH HHS R01 AA028905NIAAA NIH HHS U01 AA026934NIAAA NIH HHS U01 AA026980NIEHS NIH HHS T32 ES011564NIGMS NIH HHS P20 GM113226NIH HHS R01AA028905; U01AA026934, 1U01AA026926-01, 1U01AA026980-01; T32ES011564, F31AA028423; F32AA027950, K99AA030627
6 · The paper itselfAbstract
Alcohol-associated liver disease (ALD) is a chronic condition caused by excessive alcohol consumption, with limited effective pharmacological treatments currently available. The inhibition of soluble epoxide hydrolase (s-EH) has emerged as a promising therapeutic strategy in experimental ALD. In this study, we developed a novel liver-targeted formulation of the s-EH inhibitor
Indexed as
alcohol-associated liver diseaseliposomesliver specific deliverysoluble epoxide hydrolase
Identifiers
PMID41007411
PMCPMC12467949
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390